ArticleBulletin of experimental biology and medicine2025
Assessment of Extracellular Genomic and Mitochondrial DNA in Follicular Fluid of Women Depending on the Type of Final Oocyte Maturation Trigger in ART Programs.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the content of extracellular genomic and mitochondrial DNA (ec-gDNA and ec-mtDNA) in the follicular fluid (FF) of women after using two types of triggers for final oocyte maturation: human chorionic gonadotropin (hCG) and gonadotropin-releasing hormone agonist (GnRHa). The study included 43 women aged 21-35 years with preserved ovarian reserve according to hormonal profile and ultrasound examination, who were divided into two groups depending on the type of trigger: hCG at a dose of 10,000 IU (group 1; n = 30) and GnRHa at a dose of 0.2 mg (group 2; n = 13). From each patient, a sample of FF was obtained during transvaginal puncture from a dominant follicle without blood admixture. The content of ec-gDNA and ec-mtDNA was measured by qPCR. At the first stage, a positive correlation was found between the content of ec-gDNA and ec-mtDNA and the level of anti-Müllerian hormone, as well as between the level of ec-mtDNA and the number of oocytes. In patients reveiving GnRHa, the level of ec-mtDNA was significantly higher. There were no significant differences between the groups in the level of free ec-gDNA. The identified differences in ec-mtDNA in FF not only indicate different mechanisms of action of the used drugs, but also offer hope for the development of more precise approaches to the use of FF at the embryological stage of ART infertility treatment programs.
Indexed as
Identifiers
40682647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.